NASDAQ: SLGL - Sol-Gel Technologies Ltd.

Rentabilidad a seis meses: -19.11%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción Sol-Gel Technologies Ltd.


Acerca de la empresa Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.

más detalles
The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

IPO date 2018-01-23
ISIN IL0011417206
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sol-gel.com
Цена ао 0.559
Cambio de precio por día: +3.97% (0.529)
Cambio de precio por semana.: +5.77% (0.52)
Cambio de precio por mes: -0.9009% (0.555)
Cambio de precio en 3 meses.: -50.89% (1.12)
Cambio de precio en seis meses: -19.11% (0.6799)
Cambio de precio por año: -43.88% (0.98)
Cambio de precio en 3 años.: -92.51% (7.34)
Cambio de precio en 5 años.: -94.69% (10.35)
Cambio de precio desde principios de año.: -40.87% (0.9301)

Subestimación

Nombre Significado Calificación
P/S 20.92 1
P/BV 0.8411 9
P/E 0 0
EV/EBITDA -0.9182 0
Total: 4.63

Eficiencia

Nombre Significado Calificación
ROA, % -60.15 0
ROE, % -70.48 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.057 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % -93.21 0
Rentabilidad Ebitda, % 15.39 3
Rentabilidad EPS, % -20.18 0
Total: 1



Supervisor Título profesional Pago año de nacimiento
Dr. Alon Seri-Levy Co-Founder, CEO & Director 411k 1961 (64 año)
Mr. Gilad Mamlok Advisor 367k 1968 (57 años)
Dr. Itzik Yosef Chief Operating Officer 236k 1976 (49 años)
Mr. Moshe Arkin Executive Chairman of the Board N/A 1953 (72 año)
Prof. David Avnir Co-Founder N/A
Ms. Tamar Fishman Jutkowitz VP & General Counsel N/A 1976 (49 años)
Dr. Karine Neimann VP of Projects & Planning and Chief Chemist N/A 1971 (54 año)
Mr. Eyal Ben-Or Chief Financial Officer

DIRECCIÓN: Israel, Ness Ziona, 7 Golda Meir Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.sol-gel.com